Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + tamoxifen
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + tamoxifen is a combination therapy under investigation for the treatment of estrogen receptor-positive (ER+) breast cancer, particularly in patients who have developed resistance to hormone therapy. Pembrolizumab is a humanized monoclonal antibody that targets and inhibits the programmed cell death protein 1 (PD-1) receptor on T-cells, thereby blocking immune checkpoint signaling and enhancing anti-tumor immune responses. Tamoxifen is a selective estrogen receptor modulator (SERM) that antagonizes estrogen receptors in breast tissue, inhibiting the growth of ER+ cancer cells. This combination aims to leverage both immunotherapy and endocrine therapy mechanisms to improve outcomes in hormone-resistant breast cancer[1][3][6].
- Brand names
- Keytruda
- Other names
- pembrolizumabtamoxifen
02
Targets
ESR1 (ERα)ESR2 (ERβ)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + tamoxifen.